Advertisement
About Alseres Pharmaceuticals, Inc.
Alseres Pharmaceuticals, Inc. (ALSE) is engaged in the development oftherapeutic and diagnostic products primarily for disorders in the centralnervous system (CNS). The Company maintains a world-class intellectualproperty position in the field of regenerative therapeutics. The Company'senergy and focus is reflected in several important initiatives. Cethrin, arecombinant-protein-based drug designed to promote nerve repair after acutespinal cord injury, demonstrated positive interim results in a Phase I/IIaclinical trial. The Company's research and pre-clinical programs include,Inosine for the treatment of spinal cord injury and stroke, Oncomodulin forthe treatment of ocular injury and disease and research programs directed at anumber of regenerative therapies including bone repair. The Company has arobust molecular imaging development program targeting diagnosis ofParkinson's disease and potentially dementia. The Company's lead molecularimaging product candidate is Altropane which is in Phase III clinical trialsfor the diagnosis of Parkinsonian Syndromes including Parkinson's Disease.The Company has research collaborations with Harvard Medical School andChildren's Hospital Boston.
Advertisement
Alseres, Cethrin and Altropane are registered trademarks of AlseresPharmaceuticals, Inc.(Logo: http://www.newscom.com/cgi-bin/prnh/20080813/NEW056LOGO ) A live webcast will be available at: http://www.wsw.com/webcast/rrshq14/alse For more information on the conference and speaking companies please go to http://www.rodm.com/conferences?id=19
SOURCE Alseres Pharmaceuticals, Inc.